156755-37-2 Usage
Description
BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)is a complex organic compound with a unique molecular structure. It is characterized by its benzene and methanol components, along with a chiral center at the 1R position. The molecule also features a bis(1-methylethyl)amino group and a phenylmethoxy group, which contribute to its specific properties and potential applications.
Uses
1. Used in Pharmaceutical Industry:
BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs targeting specific receptors or enzymes.
2. Used in Chemical Research:
BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)is also utilized in chemical research for studying the properties and reactivity of complex organic molecules. It can serve as a model compound for understanding the behavior of similar structures and their interactions with other molecules.
3. Used in the Synthesis of Fesoteridone:
BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)is an impurity in the synthesis of Fesoteridone (F321300), a muscarinic receptor antagonist used for the treatment of Lower Urinary Tract Symptoms (LUTS). Its presence in the synthesis process may affect the purity and efficacy of the final product, making it important to monitor and control its levels during production.
Check Digit Verification of cas no
The CAS Registry Mumber 156755-37-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,7,5 and 5 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 156755-37:
(8*1)+(7*5)+(6*6)+(5*7)+(4*5)+(3*5)+(2*3)+(1*7)=162
162 % 10 = 2
So 156755-37-2 is a valid CAS Registry Number.
156755-37-2Relevant articles and documents
Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand
Kawamura, Shuhei,Ito, Yoshihiko,Hirokawa, Takatsugu,Hikiyama, Eriko,Yamada, Shizuo,Shuto, Satoshi
, p. 4020 - 4029 (2018/05/07)
We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.
PROCESS FOR THE PREPARATION OF FESOTERODINE
-
Paragraph 0032; 0048, (2015/01/07)
The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of Fesoterodine from O-benzyl tolterodine.
PROCESS FOR THE PREPARATION OF FESOTERODINE OR ITS SALTS
-
, (2013/04/13)
The present invention relates to a process for the preparation of fesoterodine or its salts.
